Podcasts about PD

Tired of offering the same old professional development to your teachers? Want to mix things up and try something new? On this episode of The Coaching Podcast, we're discussing the PD opportunities you might be missing. You'll learn ways to deliver engaging professional learning. Join me as I share my experiences with school-wide in-service, after-school PD, and book studies. Click now to listen to the episode! -Chrissy Beltran Buzzing with Ms. B InstagramBuzzing with Ms. B TpTThe Coaching Podcast Show Notes Thank you for listening to Buzzing with Ms. B: the Coaching Podcast. If you love the show, share it with a coach who would love it too, subscribe to this podcast, or leave me a review on iTunes! It's free and it helps others find this show, too. Happy coaching! Podcast produced by Fernie Ceniceros

This week's guest, Tom Schimmer, dives into the frequent struggles and misperceptions of assessment practices. Tom provides excellent strategies to help provide feedback to your students and how to complete this important strategy in a timely manner.     In this episode, we discuss: Frequent Mistakes in the World of Grading, Rubrics, and Assessments Student Investment through Assessment And his Newly Released Book, Concise Answers to Frequently Asked Questions about Assessment and Grading About Tom Schimmer: Tom Schimmer is an independent education author, speaker, and consultant from Vancouver, BC. Over the course of his career he has been a classroom teacher, school administrator, and district level leader. Tom is an internationally recognized leader and expert in the areas of assessment, grading, RTI, and educational leadership. He has delivered both keynote and workshop sessions at several national and international conferences. As well, Tom has worked directly with schools and school districts throughout Canada, the United States, Vietnam, China, Myanmar, Thailand, Japan, South Korea, Qatar, Bahrain, India, the U.A.E., the U.K., Russia, Singapore, Spain, Kuwait, Ethiopia, Kenya, South Africa, and Nigeria. He is the author & co-author of six books, including best-seller Grading from the Inside Out: Bringing accuracy to student assessment through a standards-based mindset, and his latest release, Growing tomorrow's citizens in today's classrooms: Assessing seven critical competencies. Follow Tom Schimmer: Website: http://www.tomschimmer.com (www.tomschimmer.com) Twitter: https://twitter.com/TomSchimmer (@TomSchimmer); https://twitter.com/TomSchimmerPod (@TomSchimmerPod) Instagram: https://www.instagram.com/tomschimmerpodcast/?hl=en (@tomschimmerpodcast) Facebook: https://www.facebook.com/TomSchimmerPod (Schimmer Education) Linkedin: https://www.linkedin.com/in/tom-schimmer-5767133a/ (Tom Schimmer) YouTube: https://www.youtube.com/channel/UCojQry-6Yi4FFMTzDH88uZQ?sub_confirmation=1 (Tom Schimmer Podcast) https://www.amazon.com/Frequently-Questions-Assessment-Challenging-Effectively/dp/1954631057?crid=2VKKZOWFCXMTW&keywords=Tom+schimmer&qid=1656680090&sprefix=tom+schimmer%2Caps%2C128&sr=8-10&linkCode=ll1&tag=aspirewebsite-20&linkId=57a8ec95deacec1661b2ead47a7f5497&ref_=as_li_ss_tl https://www.amazon.com/Grading-Inside-Out-Assessment-Standards-Based/dp/1936763850?crid=2VKKZOWFCXMTW&keywords=Tom+schimmer&qid=1656680090&sprefix=tom+schimmer%2Caps%2C128&sr=8-2&linkCode=ll1&tag=aspirewebsite-20&linkId=9abcee3d38ffccd93c6eeaba54abc051&ref_=as_li_ss_tl https://www.amazon.com/Essential-Assessment-Achievement-Classroom-Understanding/dp/1943874492?crid=2VKKZOWFCXMTW&keywords=Tom+schimmer&qid=1656680090&sprefix=tom+schimmer%2Caps%2C128&sr=8-5&linkCode=ll1&tag=aspirewebsite-20&linkId=b0c60b1bc422ecbe7b1ae5201150a944&ref_=as_li_ss_tl [caption id="attachment_3508" align="alignnone" width="1024"]https://joshstamper.com/wp-content/uploads/2021/06/Aspire-Swag-Website-Image-update-6.18.21.png () Aspire: The Leadership Development Podcast Swag, Joshua Stamper, Teach Better[/caption] NEW Aspire Swag with Discount Code: ASPIRE  Tee-Shirts and Drinkware: https://teachbetterswag.com/collections/aspire-the-leadership-development-podcast (ASPIRE: The Leadership Development Podcast)   This post contains affiliate links. When you make a purchase through these links, The Aspire Podcast gets a small percentage of the sale at no extra cost to you. Need a Presenter for a conference or school PD? https://joshstamper.com/contact/ (Contact Joshua Stamper ) for presentations on Restorative Practices, Leadership Development, and Innovative campus systems. Watch my session on Trauma Informed, restorative and social emotional practices...

O calendário da liturgia antiga dedicava o dia 1.º de julho à Festa do Preciosíssimo Sangue de Nosso Senhor Jesus Cristo. Mesmo após a reforma litúrgica, no entanto, é bastante salutar que mantenhamos viva esta devoção, cuja origem consta nas próprias Escrituras: “Porque vós sabeis que não é por bens perecíveis, como a prata e o ouro, que tendes sido resgatados da vossa vã maneira de viver, recebida por tradição de vossos pais, mas pelo precioso sangue de Cristo.” ( 1 Pd 1, 18) Esta homilia foi feita pelo Padre Paulo Ricardo no dia 1º de julho de 2016, durante Missa votiva do Preciosíssimo Sangue de Nosso Senhor, na Paróquia Cristo Rei, de Várzea Grande (MT).

Here are the highlights from June 2022 on the #InnovatorsMindset Podcast! Lainie Rowell https://www.youtube.com/watch?v=FkKvw_xAL-A Lainie Rowell answers questions about gratitude and explains how her new book, Evolving with Gratitude, reflects on how gratitude is more than a “fluff term.” Rowell reflects on her purpose in writing this book and shares that she writes about concepts that she wants to learn more about. This clip from a very special episode of The Innovator's Mindset Podcast: Evolving with Gratitude - The new book from Lainie Rowell shares Rowell explaining what gratitude is, why we should practice it, and how gratitude can impact our learning communities. Be sure to check out the full episode for a chance to comment and win a signed copy of Rowell's new book, Evolving with Gratitude! Moving From a Comfortable Average with George Couros https://www.youtube.com/watch?v=ayB-8U5uQm8 In this clip from the solo episode of The Innovator's Mindset Podcast, Moving from a Comfortable Average in Pursuit of an Unknown Better, George Couros shares a message from a TikTok video about the two people we need to impress. Couros shares his reflection on this message and talks about how taking risks has created more opportunities for himself in his life. Sherese Nix https://www.youtube.com/watch?v=rzJ-yYR3k04 Sherese Nix shares how she helped create a culture where every person felt valued. By creating an experience, Nix was able to get others excited about the work they were doing at the school site. Hear how Nix created an experience and increased enrollment at the school in this clip of The Innovator's Mindset Podcast: The Story You Want to Tell - A Convo with Sherese Nix. Brad Lands https://www.youtube.com/watch?v=gJFE-Snb8NE This clip from the full episode of The Innovator's Mindset Podcast: Sharing the Process of Learning - A Convo With Brad Lands shares several applicable strategies for writing a book. George Couros and Brad Lands talk about the process of writing and Lands explains what he hopes his book will provide to his readers. Rich Czyz Rich Czyz, the author of Rogue Leader, reflects on the different reasons to hold professional development. Czyz shares more about his book and how we can make PD powerful. To hear more of Czyz's stories and ideas, check out the full episode of The Innovator's Mindset Podcast: Take Control of Your PD Destiny - A Convo with Rich Czyz. Please share your thoughts with us on Twitter or Instagram at #InnovatorsMindset. More at georgecouros.ca George Couros on Twitter: https://twitter.com/gcouros George Couros on Instagram: https://instagram.com/gcouros George Couros on Facebook: https://www.facebook.com/georgecourosauthor/ George Couros on LinkedIn: https://ca.linkedin.com/in/george-couros-a5146519 For the full audio podcast: https://linktr.ee/gcouros Because of a Teacher - https://www.amazon.com/dp/194833433X?ref=exp_gcouros_dp_vv_d Because of a Teacher 2 - https://www.amazon.com/dp/194833450X?tag=onamzgeorge0f-20&linkCode=ssc&creativeASIN=194833450X&asc_item-id=amzn1.ideas.2SBTFVTBT0S6X The Innovator's Mindset: https://www.amazon.com/dp/0986155497?ref=exp_gcouros_dp_vv_d Innovate Inside the Box: https://www.amazon.com/dp/1948334127?ref=exp_gcouros_dp_vv_d Music from Bensound - http://bensound.com/

Called as an LDS/Mormon Bishop in the U.K. at just 23 years old, we will explore the effect such a calling has on someone so young. Join John Dehlin and Nemo the Mormon as they take time to get to know the man behind “Priesthood Dispatches”! PD is a man of many stories, and we can't wait to explore them with you all! If you or anyone you know is affected by abuse, please reach out to the numbers below: For help in the UK 08088 010818 For help in the USA 800.656.HOPE Show Notes: Nemo's Channel: https://www.youtube.com/c/NEMOTHEMORMON/ Priesthood Dispatches: https://youtube.com/channel/UCx5yNRufseSR_JxYC8GJ2iA ————— We are 100% donor funded! Please click HERE to donate and keep this content coming! Click here to donate monthly: $10 $25 $50 ————— MSP on Spotify MSP on Apple Podcasts MSP Blog Instagram Patreon TikTok Discord Contact Us! *MormonStories@gmail.com *PO Box 171085 Salt Lake City, UT 84117

Summer is finally here, and we are here for it! Teacher summer break is truly something that nobody outside of the profession really understands. It's a mix of emotions and if you're anything like us, you may be battling with choosing how to spend this time. Should you focus on rest? Should you use the summer months to plan and prepare for the upcoming year so you feel less overwhelmed when it's time to go back to work? Is there a middle ground? Well friends, we sent out the bat signal and called on other teachers to share their perspective and experiences with how they approach summer break. You'll get to hear straight from fellow teachers in today's episode as they answer questions like: What does summer break mean for you? What summer break rituals do you honor? What's your approach to summer PD/growth/planning for next year? What are some summer break mistakes you've made and how did you fix them? SHOW NOTES: https://www.bravenewteaching.com/home/episode106 Follow us on Instagram: @bravenewteaching

With Jane Ji of Springbay Studio and Grace Sadler of the Science Teachers' Association of Ontario How can gamification be used to connect young learners with nature? In what ways do the virtual world and real world overlap? Why is competition such an impactful tool in education? What does this all have to do with managing eco-anxiety? Jane Ji of Springbay discusses the conceptual underpinnings of her iBiome and League for Green Leaders before teacher Grace Sadler shares her and her students' experiences with Springbay's apps. They key is using virtual games as a bridge to the natural world, not a replacement for direct contact with it. There's lots to unpack and we do our best in the two discussions featured in this episode. Guests: Jane Ji is an educational game designer, naturalist, and facilitator for learning-by-doing through play. As a co-founder of Springbay Studio, she works with her team, focusing exclusively on climate education. She has created the award-winning educational game series iBiome and League for Green Leaders, the latter a one-of-its-kind online climate action platform for children around the world to compete to reduce their carbon footprints. Jane invites children to build virtual habitats, learn about how humans impact the environment, and empowers them to reduce their eco-footprint by making sustainable real-life choices. She delivers state-wide PD for teachers in Washington State and supports teachers from Toronto District School Board and various parts of the US with workshops on adding engagement and empowerment to inquiry-based learning. Graziella (Grace) Sadler has been teaching for 15 years, and this has included seven years in a primary/junior science and technology position. She is the Vice President of The Science Teachers' Association of Ontario (STAO) and Judging Coordinator for the York Region Science and Technology Fair. She currently teaches Grade 10 Science with the Toronto Catholic District School Board at Monsignor Percy Johnson Catholic Secondary School. 

‘Ndryshe' erdhi dhe këtë episod me dy të ftuar shumë të veçantë, Alfred Lela në një intervistë për të folur për pozicionin e ri në Partinë Demokartike dhe jo vetëm. Ai tashmë është drejtor i Zyrës së Shtypit dhe Komunikimit në PD. Në pjesën e dytë ‘pyetjeve pikante' të Salsanos dhe Adit iu përgjigj aktivistja dhe ish-drejtoresha e Burgut të Grave 325, Xhoi Jakaj.

In this bite sized PD, we'll talk about your uniqueness and believing in yourself including: how your uniqueness is a GOOD thing resources to help you move forward action steps to take The resource this week is Elementary Music Teacher Coaching week. It's happening June 26-July 3 right here: https://subscribepage.com/elementarymusiccoachingweek2022

In this episode, we explore using technology in your clinical practice in a really practical and realistic way with Dr. Kelly Bower who completed her PhD in technology use in rehabilitation. Join us as we discuss Wii, Kinect, newer rehab-specific devices, the evidence base, barriers & facilitators in the clinic and what patients get out of tech - be ready for some surprises here! Kelly also shares her journey through PhD to educator & researcher whilst remaining a clinician. Her story will help others searching for a similar path.Career pathwayPhd research – Wii balance board as Ax & interventionUsing Wii balance board as a force platform or as a clinical OMThe motivation of tech for both intervention and tracking progressWhat is it about tech that is interesting?What are the limitations?Linking use of tech to goals – a tailored interventionEvidence base variabilityClinicians' thoughts on techAdvice for addressing barriersBest devices?Kelly developing a video gameEmerging tech rehab devicesHow Kelly balances her workload (pun intended!)

Učí Biblia niečo o veku Zeme? Ako pracovali takzvaní chronológovia? A prečo mnohí kresťania prijímali a prijímajú mladý vek Zeme? ----more---- Prečítajte si túto dávku aj ako článok na SME. [čoskoro] Súvisiace dávky PD#164: Plochozemisti, https://bit.ly/davka164 PD#158: Kreacionizmus, https://bit.ly/davka158 PD#155 Rasy a Genezis II. https://bit.ly/davka155 PD#151 Rasy a Genezis https://bit.ly/davka151 PD#84: Svet pred Darwinom, https://bit.ly/davka84 PD#76: Kopernik, https://bit.ly/davka76 Použitá a odporúčaná literatúra  Answers in Genesis, ‘Young-Earth Creationist View Summarized And Defended', 2011. Barr, ‘Why the World Was Created in 4004 B.C.', 1985. Blancke et al., ‘Creationism in Europe: Facts, Gaps, and Prospects', 2013. Numbers, Creationists, 2006. Sarna, Understanding Genesis, 1970. Scientific American, 'Creationism Invades Europe', 2016. Walton, The Lost World of Genesis One, 2009. *** Baví ťa s nami rozmýšľať? ❤️ Podpor našu tvorbu ľubovoľným darom, https://bit.ly/PDdar, alebo cez Patreon, https://bit.ly/PDtreon, a čo tak štýlový merch, https://bit.ly/mercPD? Ďakujeme za podporu!

PD is joined by Burkus - coming live from vacation! - to break down Colorado's dominant performance to clinch the Stanley Cup. Later, we highlight the most intriguing prospects the Blue Jackets could select in the NHL Draft. Check out more from The Cannon on our site and on Twitter. Learn more about your ad choices. Visit podcastchoices.com/adchoices

People with Parkinson's disease (PD) often notice that their symptoms are worse when they are under stress. In addition to life stress, people with PD may experience anxiety as part and parcel of their PD itself, caused by chemical imbalances in the brain. Anxiety and stress are two different things, but can often manifest themselves in similar ways, making it challenging to tell the difference. Daniel identifies his anxieties and how they lead to stress. Since one of his personal goals is to "Speak Life" then it's very important for him to strike a balance. However, if he is not able to rest then the result is more complications with the progression of P.D. What can we do to lower anxiety, lower blood pressure, and improve our quality of life? Add your experience and suggestions to the conversation in this Parkinson's podcast. If you would like to leave Daniel a voice message and you live in the U.S. call 1-706-873-1656. Email us at parkinsonsandmepodcast@gmail.com or visit our site parkinsonsand.me --- Send in a voice message: https://anchor.fm/parkinsonsandme/message

In part two this ASCO Education Podcast episode, hosts Dr. David Johnson and Dr. Patrick Loehrer continue their conversation with Dr. Richard Pazdur, director of the U.S. Food and Drug Administration's Oncology Center of Excellence, focusing on his leadership and vision for improving cancer care worldwide. The conversation includes reflection on drug toxicities, approval processes, and complexity of clinical trials. If you liked this episode, please subscribe. Learn more at https://education.asco.org, or email us at education@asco.org.   TRANSCRIPT Dr. Pat Loehrer: Hi. I'm Pat Loehrer, the Director of Global Oncology and Health Equity at Indiana University. Dr. Dave Johnson: And hi. I'm Dave Johnson at UT Southwestern in Dallas, Texas. Dr. Pat Loehrer: This is the second half of our Oncology, Etc. conversation with Dr. Rick Pazdur, who's the director of the FDA's Oncology Center of Excellence. In Part 1, we chatted with Dr. Pazdur about his upbringing and his early career. Today, we're going to focus on his leadership and vision for improving cancer care worldwide. But first, we'll discuss how cancer has impacted his life personally.   I want to flash-forward. I had the pleasure of knowing Mary. And there was no question, if you had a problem in oncology, you would go to Mary and not Rick Pazdur when you were a house staff member. But moving forward a bit, I'm not sure if all the listeners know that Mary came down with ovarian cancer. Dave himself had cancer. My wife had breast cancer. It is incredibly hard to be an oncologist I think when your spouse or someone who's close to you has cancer, and particularly, being married to a medical oncology nurse. Maybe just share a little bit about that journey of being a husband of a- Dr. Richard Pazdur: Yeah. It is interesting because going back to the Rush story, the first patient that my wife and I had in common, and this is so ironic, was a patient with ovarian cancer. The last patient that we had in common was her, which is some ironic fate, so to speak. And the story began of her illness was right around Labor Day. We had gone to Chicago in February driving back from Chicago. I noticed that she kept on taking a whole bunch of Tums and then saying - Oh, I just got a lot of GI symptoms, and she went to see her gastroenterologist or GP and he said, ‘Oh, this is just, you know, indigestion.' And two weeks after that or not even that, she was in the hospital with a massive amount of ascites, needed an intensive care unit. It was readily apparent just on getting her CA 125 what she had and she wound up one day in debulking surgery and then IP chemotherapy, etc. I think something that I learned, and I think we knew from the very beginning that this was not going to be a curable illness, and how to deal with that on an emotional level. And I have to give my wife credit. She spared me a lot of the emotion because she was such a strong person. She made all of her own calls as far as what she wanted. She would ask me what I thought, but she would do her own research, she would go to her own doctors' appointments. She said, ‘You don't really need to come with me. I'm self-sufficient.' She was very much interested in helping other cancer patients, and after she died, I think one of the most cherished conversations I had was a group of women that came to me and said how much she helped them during their support group because she was a nurse. She knew she was dying. She had emotional maturity not to fall apart but to accept the inevitable in a very strong way. My wife was a very religious person, had gone to Catholic schools, really embraced religion during those terminal years basically. And I think that was a great sense of comfort to her. But it did teach me a lot of lessons when you take care of somebody that has cancer, and that is, what a bad job we do with drug toxicities. Drug toxicities to medical oncologists and especially the people at the FDA are numbered, Grade 3, Grade 4, Grade 1. These toxicities are tolerable, tolerable to who, so to speak. And how to manage these toxicities and how they interrupt your life is one of the lasting experience I have, which I always will remember. And that has been one of my roles recently is forming several programs that we have in the OCE to look at dosing, to look at what is this definition if the drug is tolerable or well-tolerated or if the toxicities could be managed. I always say, yeah, every toxicity could be managed, even death. You call the undertaker to manage it. So what do you really mean by that statement. But I think the issue of toxicity is an important one. And then also going on clinical trials and having people considering what you want to go on, what risk you want to take, and what is actually in the informed consent and how meaningful that is. Dr. Dave Johnson: Really glad you brought that up, Rick. That matches my own experience with lymphoma and going through chemotherapy. And as an oncologist, one would think I would know what the side effects are. I'd recounted them dozens and dozens of times to people over the years, but until you've actually experienced them either personally or up close as you did with Mary, it's impossible to fully understand. I'll give you one example. Fatigue. Everybody thinks they know what fatigue is, but until you've had chemotherapy-induced fatigue, the fatigue that never abates, you just don't understand what it is. It's debilitating in ways that are unimaginable to most people. So I'm sure that experience certainly shaped your view and your role at the FDA. Dr. Richard Pazdur: Correct. Dr. Dave Johnson: I wonder, if you might share, you initiated a number of programs recently, including programs to try to improve coordination and co-operation amongst the pharmaceutical companies. Could you speak to some of those programs for us? Dr. Richard Pazdur: I think one of my favorite programs is Project Orbis. Project Orbis is an idea I had when I was walking down the street. It just hit me. When I came to the FDA, one of the things I rapidly noticed is how isolated the FDA was, even from the rest from the regulatory agencies throughout the world. There was very little cross-fertilization there. So one of the very first things that I did was set up a monthly tele-conference first with the EMA, the European Medicines Agency, and then we ended on Health Canada, Australia, Japan, Singapore, you name it. And one of the things that became really apparent to me, we at the FDA got applications always first—always. That's obvious. You know why they had given it to us first? The money. That's where the finances are going to be. So we got the application first, and it could be 2 years, 18 months, 12 months, that these other countries, Canada, Australia, Switzerland, and Brazil, Israel, would get these applications. And I said, well, this isn't right, really, because these people, they have cancer. They have every right to get these medications as soon as possible, and also we have such a large agency. We have 80 to 100 oncologists that work there, and most of these agencies have one or two oncologists. So our expertise in oncology at the FDA is so much greater than these other regulatory agencies. How can we leverage that to help these other countries? So we started Project Orbis, and what it was is that companies come in and they submit an application and they simultaneously submit the same application to the countries that want to participate in the program. They are all preselected and have confidentiality agreements with each other. And we worked together on the applications, basically reviewing the applications. So we had many meetings, tele-conversations, telephone conversations with countries. So that expedites these drugs. This has really had a lasting impact because from a worldwide perspective, it's really promoted more rapid development of drugs and rapid approval of drugs, and that's important because that establishes sooner new standards of care that will impact future trials. So in addition to the humanitarian issue of improving healthcare for patients in these countries, it has an impact on the global clinical trial system by having new standards approved much faster and accepted by world authorities. Dr. Pat Loehrer: Let me just jump on that for a second, just to make a comment. Back when we were growing up, there would be like three to five drugs approved- Dr. Richard Pazdur: Yeah. Dr. Pat Loehrer: And today, it's like once a week, there's a new indication for oncologists. Dr. Dave Johnson: Our listeners have another question that might be appropriate to ask at this time. What is the most common mistake that drug companies make in their applications to the FDA or in the process of trying to get their drug approved? Is there a frequent mistake that you can advise them? Dr. Richard Pazdur: Well, they don't come and talk to us. That's number one. They want, not necessarily what the best registration pathway is, but what the quickest registration pathway is. And sometimes the quickest registration pathway, especially single arm trials, are not the best registrations pathway. So my advice is rather than playing games with the FDA, to put it in the vernacular, just do the right thing and say, what is the optimal information that patients need when I develop this drug. We're seeing a lot of problems now with various drugs where people are developing in a refractory disease setting a drug, and they plan on getting accelerated approval on a response rate. So they push and push the dose. And with a single arm study, you can't really evaluate safety that well. Everything is attributed to the drug, and they want to get the highest response rate. And they get it, and there's a confirmatory study, and the arm of the confirmatory study, the control arm may not be as toxic as theirs, and we're seeing a wave of drugs that now have inferior survival compared to controls, which probably is predicated upon, they got the wrong dose. And I think that is one of the major programs that we have, that we need to address is dosing in oncology, this ‘More is better, more is better,' and ‘Let's push the dose as high as possible.' More isn't even probably good in cytotoxic days, but certainly, not a good idea in targeted therapies and certainly not a good idea in biological therapy. So we've really got to think about dosing more, penetration of targets, what's the optimal dose rather than what's the highest dose. You know as well as I do, pharmaceutical companies want to go with the highest dose because the major hurdle is the demonstration of efficacy, even in a randomized study. So nobody wants to be blamed by saying, well, you spent $100 million on a Phase 3 study and it's negative because you used too low of a dose. But then at the end of the day, we don't have a really good tolerable dose, and it's really hard to go backwards and look at dosing after a drug was already approved because the efficacy study has already been done. Dr. Pat Loehrer: The other aspect of drug companies is not only getting the dosage there, but also the duration. There is motivation for money, and so patients are going to and- Dr. Richard Pazdur: Oh, count on that. Dr. Pat Loehrer: So it begs a question, and I know the FDA can't do this, but in other countries, there is a monetary review together with the toxicity review. Can you reflect a little bit about that to the best of your ability? Dr. Richard Pazdur: Well, even within our simpler agencies, they may communicate more than we do with CMS, but all oncology drugs that when they're approved are then paid for by CMS, okay? In these other countries, that is not so. They may get approval and then they have to go to these health assessment agencies that will decide and argue with the companies what the pricing of the drug is. I think it's a mistake, honestly, for the FDA to get into pricing. We have a hard enough time with efficacy and safety, and pricing is a very ephemeral concept because it could change on a dialing. Somebody could promise you, you should approve their drug because it's much cheaper on Monday, and on Friday, they could say, 'Oops, we made a mistake. We really think that this dose has to be X number of dollars.' And you could see competition hasn't worked well in oncology with seven PD-1 drugs approved, pricing has not really been of any movement here. Dr. Pat Loehrer: I'm sorry. Dave may have another question, but let me ask you this. Going back to the clinical trials and what industry asked you- the complexity of clinical trials is going up logarithmically compared to the way they were in the ‘70s and ‘80s. In many of the trials where we have to get all this data in order to soothe the FDA, what are your thoughts about simplifying clinical trials? Dr. Richard Pazdur: Oh yeah. I'm for it. I am for it. If you really look at it, these are not FDA requirements for the most part. The companies want them, all of this data because it's controlled. They don't want to be blamed at the end of the day for not capturing this data or that data. They have developed complicated bureaucracies, going back in my sociology days there, complicated bureaucracies to gather all of this data, the whole CRO industry to go out and pester you guys in practice by doing site visits. It's a complicated situation and it's really predicated a lot on the history and bureaucracies that have been built up and not money to strip away those bureaucracies for fear of failure, so to speak, of not catching something. Dr. Dave Johnson: So Rick, we're coming to the end of our time that we've scheduled. I actually have two questions for you. We've asked all of our previous guests, the first of which would be if you could talk to your 21-year-old self today, what advice would you give yourself? After you've done that, we'd like to know what books have you been reading lately or is there some documentary that you've seen that you would recommend to us and our listeners? Dr. Richard Pazdur: I would tell myself, when I was 21 years old, relax and be less anxious. All things pass. I think we get so anxious when we're young about relatively small things. I remember my first ASCO presentation, I was petrified. My heart was beating out of my chest. I was sweating. And like relax. It's one of a thousand presentations at ASCO. We tend to magnify things, and I think age puts things in perspective. This in the reality of the world is a small thing, and people probably won't even remember it. Dr. Dave Johnson: Excellent advice. Dr. Richard Pazdur: My favorite author that I'm reading now for the last couple of months is a presidential historical author, Doris Kearns Goodwin. I think many of you know, she's written many books. I love her writing style. And I like non-fiction. I like biographies and I like history books, history stories rather than mysteries or things like that, fantasy books. The two books that I really enjoyed, the first one was No Ordinary Time: Franklin and Eleanor Roosevelt: The Home Front in World War II. I don't know if anybody's read that. It's an excellent book. Most of our attention in World War II is directed toward Europe and what was going on in Europe, the battlefields, etc., which I'm not a big fan of reading about battles and stuff, but this was what was going on in The White House and the relationships of all of the people that came there. It was like a hotel almost with the personalities that were flowing through including Churchill and various princes and queens, etc. But also the interesting relation, the fascinating relationship that Eleanor and Franklin Roosevelt had, I don't know how to describe the relationship. It truly was an unconventional relationship based on some past history that they had of affairs etc., but it was just a fascinating one. The best book, though, again I'm reading now, is written also by Doris Kearns Goodwin, and it is Lyndon Johnson and the American Dream. Doris Kearns Johnson was his biographer and spent a great deal of time with him in The White House as well as when he left The White House. But it's an excellent book on management and reading people, success. One of the things that is most interesting about Lyndon Johnson, and especially when he was running the senate before he became president, was his ability to know what motivated people and how to use that to form a consensus. Does this person want to go on this trip. I'll give it to him and then he could help me with this. Does this person want to go to this party or get on this position in congress? So it was really a skillset that he had, which I think most leaders need to know. You have to motivate people. You can't lead by an autocratic masthead, but you've got to lead from what do people want and to make sure that they feel you have a personal relationship with them. As I say to my staff, everything in life is personal—everything. Dr. Dave Johnson: Well, it's been a great session, Rick. We so much appreciate your willingness to spend time with us. We wish we had twice as much time. I'm sure we could go on for hours. Thanks again, and we appreciate all you do at the FDA. You've been a fabulous leader, and we hope you continue on for many years to come. Dr. Richard Pazdur: Thank you so much, Dave, and thank you so much, Pat. Dr. Pat Loehrer: Great to see you. Dr. Dave Johnson: Pat, before we leave, any idea why our patients seem to get sick on Saturday and Sunday? Dr. Pat Loehrer: I have no clue. Do you know the answer, Dave? Dr. Dave Johnson: Yes. They have a weekend immunity. Thank you for listening to the ASCO Education Podcast. To stay up to date with the latest episodes, please click subscribe. Let us know what you think by leaving a review. For more information, visit the Comprehensive Education Center at education.asco.org. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.    

A cura di Daniele Biacchessi Dopo una sconfitta elettorale le ore sono sempre quelle più incerte. C'è chi mette in campo un mea culpa da schieramento sfilacciato. "Spiace per le città perse", dice Matteo Salvini. "Basta litigare, vediamoci al più presto", sostiene Giorgia Meloni. Intanto Berlusconi convoca i vertici di Fi per fare il punto sulle elezioni amministrative. Ma c'è chi esulta come il segretario del Pd Enrico Letta: "Grande successo del Pd e del centrosinistra". La verità sta come sempre nel mezzo. I dati reali segnalano un crollo netto dell'affluenza, ridotta al 42%: vuol dire che ai seggi si sono presentati 4 italiani su dieci. Non vuol dire però che il voto non abbia un valore politico e non possa rappresentare un segnale forte. Verona, Monza, Carrara, Catanzaro, Parma, Piacenza, Alessandria, Cuneo, vanno al centrosinistra. Gorizia, Barletta, Frosinone, Lucca sono del centrodestra. A Como e Viterbo vincono i candidati civici. Il centrodestra è certamente la coalizione battuta tra primo e secondo turno: massima litigiosità, totale assenza di una leadership che possa tenere la coalizione, personalismo e protagonismo. Nel centrosinistra, le cose migliorano, ma solo pochissimo. Il campo largo, assunto come modello politico da Enrico Letta, è troppo labile e il Pd senza l'accordo con il M5s potrebbe apparire come un gigante di carta senza un'anima. Credits: Agenzia Fotogramma

Do you have students who struggle with math in your classroom? How can we get them to take the earbuds out and actually put in effort in our classes? On today's episode we talk to Juliana Tapper from CollaboratEd and cover misconceptions about teaching students who struggle with math plus get some actionable tips about how to get these students more engaged. Juliana taught Algebra 1 and Math Intervention at high schools in South Central Los Angeles, East San Jose, and Denver - and had a 3 years stint as a district math coach and TOSA - before leaving the classroom in 2018 to provide PD for schools and districts that teachers actually can't wait to implement. You'll Learn: Why spending time on classroom culture and community ISN'T a waste of time;Why grading practices have a great impact on outcomes for struggling learners than you may realize; and,Actionable tips about how to get students who struggle engaged.Resources: Free guide - 10 math intervention strategies: https://www.collaboratedwithjuliana.com/mathguide Blog: https://www.collaboratedconsulting.org/blogRethinking math assessment workshop: https://www.collaboratedwithjuliana.com/rma Instagram: https://www.instagram.com/collaborated.with.juliana/ Workshops: https://www.collaboratedconsulting.org/workshops Are you a district mathematics leader interested in crafting a mathematics professional learning plan that will transform your district mathematics program forever? Book a time to chat with our team!Create engagement while fuelling students sense making by using Make Math Moments ready-made lessons and units. Access our vast catalogue of lessons for elementary through high school math classes.Check the catalogue here --> https://makemathmoments.com/tasks/ Create engagement while fuelling students sense making by using Make Math Moments ready-made lessons and units. Access our vast catalogue of lessons for elementary through high school math classes.Check the catalogue here --> https://makemathmoments.com/tasks/

Summer is here which means you can finally rest after the long and demanding school year! We know the routine - hurry, stress, and go, go, go all school year so when summer comes, we just want to relax, recharge, and unplug. And we should! But if you're anything like me, you need something to work on to keep you in some sort of routine. In this episode, I discuss how to make the most of your restful summer by setting small, manageable goals so that you can be more prepared going back to school. I give you 3 easy to work on goals that will help cut down on the stress that fall often brings. You'll hear about using your increased mental clarity and creativity to make adjustments for next year, completing a task that you just don't have time for during the school year, and checking a must-do task off your list that is low pressure and doesn't require much energy from you. If you're interested in PD in the summer, I have my own professional development course that I have created specifically for secondary science teachers. Enrollment has ended for this year's summer session but I would love for you to join the waitlist so you know when I offer it again. You can sign up for the waitlist here.I would love to see you there! In the meantime, check out my other resources to help simplify your school year. Check out the show notes for all resources mentioned in this episode: https://itsnotrocketscienceclassroom.com/episode28 Download your FREE Classroom Reset Challenge.

Tune in and listen as Erica Harrell shares about her experience and knowledge with creating effective Professional Development opportunities for educators. You'll be inspired as Erica shares her challenges and wins along her education journey. https://alwaysalesson.com/wp-content/uploads/2022/06/empowering-educators-podcast-15.png ()Quotables When you are the expert…it's often hard to make the information digestible for others because you want to give so much.  Facilitators who really hit the nail on the head, get to know their learners.  When you can be willing and transparent to show all the data, that's when growth happens.  As a PD facilitator there is a time to be the GPS and a time to be the map. About Erica: Erica Harrell is the CEO of Erica Harrell Consulting, an education consulting firm created to help dedicated educators create strategic professional development plans to increase student achievement and improve staff capacity. Erica has over 12 years of experience in K-8 education. She began her career as a special education teacher and has held multiple leadership roles from instructional coach to principal to Director of Leadership Development. In all of her roles, Erica has always had the desire to grow and help others do the same. As a school leader, Erica has led teams to develop strategic and comprehensive project plans for multi-day and multi-week professional development series and coached leaders to ensure high-quality session facilitation. Under her leadership, a team of school-based leaders facilitated 4-week summer professional development with an average of over 90% of participants rating sessions and operations as “Platinum” (highest rating on 5-point Likert scale) multiple years in a row. Erica is originally from Upstate New York. She attended University of Maryland, College Park for undergrad. She holds a MEd in Instructional Leadership from Relay Graduate School of Education. Erica currently lives in Maryland with her husband and one year old son. Connect with Erica: https://www.instagram.com/ericaharrellconsulting/?hl=en (IG: @ericaharrellconsulting) Email: Info@ericaharrellconsulting.com https://www.buzzsprout.com/1783607 (Podcast: The Power of PD Podcast) Come Chat on Clubhouse! Instructional Coaching Clubhttp://www.clubhouse.com/club/instructionalcoaching (- www.clubhouse.com/club/instructionalcoaching) Join the Always A Lesson Newsletter Join http://eepurl.com/lJKNn (here) and grab a freebie! Connect with Gretchen Email: gretchen@alwaysalesson.com Blog: https://alwaysalesson.com/blog/ (Always A Lesson) Facebook: https://www.facebook.com/AlwaysALesson/ (Always A Lesson) Twitter: https://twitter.com/gschultek/ (@gschultek) Instagram: https://www.instagram.com/always.a.lesson/ (Always.A.Lesson) Linkedin: https://www.linkedin.com/in/GretchenSchultekBridgers/ (Gretchen Schultek Bridgers) Book: https://alwaysalesson.com/product/elementary-educ-101-what-they-didnt-teach-you-in-college/ (Elementary EDUC 101: What They Didn't Teach You in College) Leave a Rating and Review: This helps my show remain active in order to continue to help other educators remain empowered in a career that has a long-lasting effect on our future. https://itunes.apple.com/us/podcast/always-lessons-empowering/id1006433135?mt=2 (https://itunes.apple.com/us/podcast/always-lessons-empowering/id1006433135?mt=2) Search for my show on iTunes or Stitcher. Click on ‘Ratings and Reviews.' Under ‘Customer Reviews,' click on “Write a Review.” Sign in with your iTunes or Stitcher log-in info Leave a Rating: Tap the greyed out stars (5 being the best) Leave a Review: Type in a Title and Description of your thoughts on my podcast Click ‘Send'

Self-care is a word thrown around a lot these days in education. In the real world of teaching, answers aren't always easy. In fact, as I release this episode, "self-care" is the reason I did not go to #ISTELive that is this week. I need to focus on my health. So, it is fitting that today I discuss the reality of teaching with another teaching veteran. We share how we have navigated the stresses and struggles of teaching as we seek to live a balanced life and do what matters. In addition to the podcast, I've included some inspiring poems, quotes, and a video from the day I learned to walk this past May. I, Vicki Davis (the show host) have made some mistakes in self-care in the past year, and open up about what I've learned from those mistakes and how I'm moving forward to teach better and take better care of myself.  My hope is by being open about my own struggles and by bringing in the research that this show and blog post will help all of us teachers take better care of ourselves. Right now, this topic is more important than any education technology I could be talking about. So, take care of yourselves, teachers, this one's for you. Sponsor: In today's show, you learned more about taking care of yourself. You also learned about many courses from Advancement Courses, which has over 280 online graduate-level PD courses in not only self-care but topics for every grade level and subject area. Plus, their courses are self-paced with up to six months to complete. Go to www.advancementcourses.com/coolcat and get your 20% discount by entering the code CAT20 and sign up for your summer PD now. This time last summer I was taking a course in Computer Science that helped me implement a new course and curriculum at our school. Show Notes and Transcript: https://www.coolcatteacher.com/e786  Bio As Submitted: Stephanie Dorsey is an educator service consultant for Advancement Courses specializing in supporting teachers in the recertification and lane advancement process and advises teachers on courses that best match their professional growth needs. As a former special education teacher from Illinois, she worked in both elementary and middle school public and charter school settings for over 18 years. She received her M.Ed from the University of Colorado Denver in special education. Over the course of her career, she has been particularly interested in training other educators on effective curriculum, RTI, and universal design. Disclosure of Material Connection: This is a “sponsored podcast episode.” The company who sponsored it compensated me via a cash payment, gift, or something else of value to include a reference to their product. Regardless, I only recommend products or services I believe will be good for my readers and are from companies I can recommend. I am disclosing this in accordance with the Federal Trade Commission's 16 CFR, Part 255: “Guides Concerning the Use of Endorsements and Testimonials in Advertising."

George Couros starts this podcast with a reflection on learning norms. “All that I ask of you today is to learn in a way that you would expect from your students” - this quote is how Couros begins many of his sessions. On this episode, Couros invites Rich Czyz to talk about his new book, Rogue Leader. The two talk about the advice that we can share with educators and how we can make PD powerful. Couros asks that the learners listening to or watching this episode create something - write a blog post, share a Tweet, make a graphic…create a piece of content that demonstrates the learning you got from this episode. Czyz shares some great stories about the importance of building relationships and making learning meaningful. Links: Rich Czyz Twitter - https://twitter.com/RACzyz 4 O'Clock Faculty - https://fouroclockfaculty.com/# Rogue Leader (book on Amazon) - https://www.amazon.com/Rogue-Leader-Inspire-Professional-Development/dp/1956306099 Quotes: "Professional development should be done with, not to." - Rich Czyz "If you are trying to help people grow, you have to live that message."- Rich Czyz "When I grow is when I am talking to others and learning from them." - Rich Czyz Please share your thoughts with us on Twitter or Instagram at #InnovatorsMindset. More at georgecouros.ca George Couros on Twitter: https://twitter.com/gcouros George Couros on Instagram: https://instagram.com/gcouros George Couros on Facebook: https://www.facebook.com/georgecourosauthor/ George Couros on LinkedIn: https://ca.linkedin.com/in/george-couros-a5146519 For the full audio podcast: https://linktr.ee/gcouros Because of a Teacher - https://www.amazon.com/dp/194833433X?ref=exp_gcouros_dp_vv_d The Innovator's Mindset: https://www.amazon.com/dp/0986155497?ref=exp_gcouros_dp_vv_d Innovate Inside the Box: https://www.amazon.com/dp/1948334127?ref=exp_gcouros_dp_vv_d Music from Bensound - http://bensound.com/

Shawn and Troy share some jokes, summer, and more. Dave brings the pun game to Science. 

This week's guest, Dr. Michael Nagler, shares how he uses the motto “Think Differently” to shift his district into a problem solving and innovative group of educators, which prepare the students to be successful in their unknown future careers.    In this episode, we discuss: Standards Based badge books for k-4th grade New model of High school called Synergy And his book, The Design Thinking, Entrepreneurial, Visionary Planning Leader About Dr. Michael Nagler: Michael is the Superintendent of the Mineola School District, a suburb of NYC. Mike began his career as a social studies teacher in NYC.  While teaching he earned his doctorate from Columbia University and accepted an administrative position with Mineola in 1999. He believes strongly in the district's mission to inspire students to become lifelong learners that exhibit strength of character and contribute positively to a global society. During his twenty three years with the district, he has been a big proponent of using technology to engage students in rigorous content. All five schools in Mineola have been recognized as Apple distinguished schools.  Mineola is also a member of the League of Innovative Schools, Dr. Nagler is the Chairperson of the Advisory Board. Mineola was one of the first schools in the State to implement a comprehensive computer science curriculum starting in kindergarten. Mineola is also at the forefront of digital student portfolios.  Dr. Nagler recently utilized the Districts coding platform to create his own digital portfolio. http://michaelnagler.oyosite.com/ ( http://michaelnagler.oyosite.com) Dr. Nagler was the 2020 New York State Superintendent of the Year and was a Finalist for the 2020 National Superintendent of the Year.   Follow Dr. Michael Nagler Website: http://www.mineola.k12.ny.us (www.mineola.k12.ny.us)  Twitter:  @NaglersNotions https://twitter.com/NaglersNotions (https://twitter.com/NaglersNotions) YouTube: https://www.youtube.com/channel/UChA8OC_NBFjy13ip89S2cwg (https://www.youtube.com/channel/UChA8OC_NBFjy13ip89S2cwg) https://www.amazon.com/Design-Thinking-Entrepreneurial-Visionary-Planning/dp/B09XT6J4JH?crid=S587QGCID7A5&keywords=dr+michael+nagler+book&qid=1656169071&sprefix=dr+michael+nagler+book%2Caps%2C137&sr=8-1&linkCode=ll1&tag=aspirewebsite-20&linkId=32d34df7da9d778d696884d6c6d6e18e&language=en_US&ref_=as_li_ss_tl   [caption id="attachment_3247" align="alignnone" width="1024"]https://joshstamper.com/wp-content/uploads/2021/01/Aspire-Swag-Website-Image.png () Aspire Swag, Teach Better Team, Joshua Stamper, Aspire: The Leadership Development Podcast[/caption] NEW Aspire Swag with Discount Code: ASPIRE  Tee-Shirts and Drinkware: https://teachbetterswag.com/collections/aspire-the-leadership-development-podcast (ASPIRE: The Leadership Development Podcast)     This post contains affiliate links. When you make a purchase through these links, The Aspire Podcast gets a small percentage of the sale at no extra cost to you. Need a Presenter for a conference or school PD? https://joshstamper.com/contact/ (Contact Joshua Stamper ) for presentations on Restorative Practices, Leadership Development, and Innovative campus systems. Watch my session on Trauma Informed, restorative and social emotional practices athttp://www.teachsummit.com/stamper ( www.teachsummit.com/stamper)   Follow the Host, Joshua Stamper: Contact:https://joshstamper.com/contact/ ( https://joshstamper.com/contact/) Twitter:http://www.twitter.com/Joshua__Stamper ( www.twitter.com/Joshua__Stamper) Instagram:http://www.instagram.com/joshua__stamper ( www.instagram.com/joshua__stamper) Linkedin:http://www.linkedin.com/in/joshua-stamper/ ( www.linkedin.com/in/joshua-stamper) Facebook:https://www.facebook.com/AspirePodcast ( https://www.facebook.com/AspirePodcast)...

Podcast of Thursday 6/23/22 show   The Young Onset Parkinson's Network (YOPN) and radioparkies.com are proud to present the story of a rising personality in the Parkinson's community, Jeremy McDonald. Jeremy a talented musician initially started a YouTube channel to showcase his music then he was diagnosed with PD. So Jeremy decided to change the focus to spreading awareness and help others with this condition using his wit, and sense of humor all the while being serious when needed. Check out his videos by searching JEREMY MCDONALD ON YOUTUBE  

Larry Gifford is President and Co-Founder of PD Avengers. He was diagnosed with young-onset Parkinson's disease in August 2017 at the age of 45. Larry is active with the Parkinson's Society British Columbia and sits on the board of directors for the Pacific Parkinson's Research Institute. He believes in the power of storytelling hosting, "When Life Gives You Parkinson's," a podcast that documents his experience living and working with PD, which was a finalist for the Canadian Podcast Awards. Sponsor: www.SeniorCareAuthority.com

Today's show focuses on Clarence Thomas' ruling on guns, his wife Jinny Thomas and their perverse relationship with his former law clerk John Eastman who appears to be the architect of Donald Trump's conspiracy to overthrow the results of the 2020 president election. Plus, Former Assistant Attorney General Jeffrey Clark's home raided by FBI; Is Trump finished?; Senate passes gun reform bill; Supreme Court overturns gun reform; Roe v. Wade braces for impact; Guests With Time Stamps (00:28) David Does the News: The truth about Chicago's gun murder rate; Why Jeffrey A. Rosen, the former acting attorney general; Richard P. Donoghue, the former acting deputy attorney general; and Steven A. Engel, the former assistant attorney general for the Office of Legal Counsel are not heroes; Supreme Court voids New York's gun law; Supreme Court Justice Clarence Thomas obscene relationship with John Eastman, the unhinged architect of Donald Trump's criminal conspiracy to overturn the 2020 election (56:16) Dan Frankenberger and David kill time (1:05:25) Gregg Barak (author, "Criminology on Trump") Emeritus Professor of Criminology & Criminal Justice at Eastern Michigan University, Gregg Barak thinks this time they actually have Trump. (1:35:36) Professor Ben Burgis (his new book is "Christopher Hitchens: What he got right, how he went wrong, and why he still matters.") Professor Burgis talks about his big debate this Saturday night with Tim Pool, Tulsi Gabbard and James O'Keefe. (2:05:46) The Herschenfelds: Dr. Philip Herschenfeld (Freudian psychoanalyst), and Ethan Herschenfeld (his new comedy special "Thug, Thug Jew" is streaming on YouTube) How to explain this mystifying loss of any kind of moral sense in our Republican brethren. There were in the past conservatives with much different opinions on how to govern the country. But they seemed to have had a sense of integrity and honesty that has lately vanished. (2:38:38) Emil Guillermo (host of the PETA Podcast, and columnist for The Asian American Legal Defense And Education Fund) Vincent Chin plus 40 years. Juneteenth and the Golden State Warrior Millionaires. Kevin Hart investing in vegan fast food. The racism of the Big Lie and how it destroyed Shae Moss' sense of democracy (3:11:33) "USA of Distraction" written and performed by Professor Mark Steinel (3:16:33) The Rev. Barry W. Lynn (Americans United for Separation of Church and State) Member of the Supreme Court Bar, The Rev. Barry W. Lynn reviews Clarence Thomas' majority opinion today overturning New York's gun law. (4:05:54) The Professors And Mary Anne: Professors Jonathan Bick, Adnan Husain, and Ann Li. January 6 Hearings; Supreme Court; Afghanistan PLUS: ASMR for your eyeballs - Kitchen ASMR with Joe in Norway - Shop ASMR with Dave in PA (5:13:32) Professor Harvey J. Kaye ("FDR on Democracy") and Alan Minsky (executive director of Progressive Democrats of America) We livestream here on YouTube every Monday and Thursday starting at 5:00 PM Eastern and go until 11:00 PM. Please join us! Take us wherever you go by subscribing to this show as a podcast! Here's how: https://davidfeldmanshow.com/how-to-l... And Subscribe to this channel. SUPPORT INDEPENDENT MEDIA: https://www.paypal.com/biz/fund?id=PD... More David @ http://www.DavidFeldmanShow.com Get Social With David: Facebook: http://www.facebook.com/davidfeldmanc... Twitter: https://twitter.com/David_Feldman_ iTunes: https://itunes.apple.com/us/podcast/d...

In this episode, Justin Wells, a deeper learning advocate and Executive Director of Envision Learning Partners, shares insights into how school districts are using innovative principles of deeper learning to design better performance assessments to measure student success. In addition, Wells encourages school leaders and classroom teachers to design capstone experiences and a portfolio defense system at various grade levels to help "build muscle" on the path to greater equity for all students. Twitter: @jusowells. Meet Justin Wells Justin Wells is the Executive Director of Envision Learning Partners, a team of coaches who help schools and districts develop performance assessment systems guided by the principles of equity and deeper learning. Before that, he taught high school English and led teacher teams in the design and implementation of multidisciplinary projects. He is co-author of the book Transforming Schools with Common Core Standards, Performance Assessment, and Project-Based Learning (with Bob Lenz and Sally Kingston). About Dr. Greg Goins As the Founder/Host of the Reimagine Schools Podcast, Dr. Greg Goins has emerged as one of the nation's leading voices on visionary leadership and the path to transforming our schools. He currently serves as the Director of the Educational Leadership Program at Georgetown College (KY) and previously spent 15 years as a school district superintendent in Illinois. Dr. Goins is a passionate keynote speaker and is available to speak at your next education conference or school PD day. To book Dr. Goins, please send inquiries to drgreggoins@gmail.com. Twitter: @DrGregGoins. Support for Reimagine Schools Podcast You can now click HERE to "buy a bourbon" for Dr. Goins to help support this podcast. Thanks for your support! --- Support this podcast: https://anchor.fm/greg-goins/support

Dr. Diwakar Davar and Dr. Jason Luke, both of the University of Pittsburgh's Hillman Cancer Center, highlight key advances in early phase therapeutics and immunotherapy that were featured at the 2022 ASCO Annual Meeting and also address toxicities, including immune checkpoint inhibitor-associated myocarditis. TRANSCRIPT Dr. Diwakar Davar: Hello, and welcome to the ASCO Daily News Podcast. My name is Dr. Diwakar Davar, and I'm an assistant professor of Medical Oncology, specializing in melanoma and phase 1 therapeutics at the University of Pittsburgh's Hillman Cancer Center. I am the guest host of today's podcast. My guest today is Dr. Jason Luke, a colleague and the director of the Cancer Immunotherapeutics Center at the UPMC Hillman Cancer Center here.  Today, we'll be discussing advances in early-phase therapeutics and immunotherapy that were featured at the 2022 ASCO Annual Meeting.   You'll find our full disclosures in the show notes, and the disclosures of all guests on the podcast are available on our transcripts at asco.org/podcasts.  Jason, thank you for coming on the podcast today.  Dr. Jason Luke: Thanks so much for the invitation. It was a great ASCO, and I hope everyone had a good time.  Dr. Diwakar Davar: So, onto our abstracts. So, the first one that we'll be discussing, and Jason as you know we've done this before. We'll be rapidly transitioning between phase 1 therapeutics, melanoma, and advanced phase 2 and 3 trials, but you know this is something you do very well. So Abstract 2504, it's a phase 1 trial of TIM-3 inhibitor cobomilab immunotherapy and in combination with PD-1 inhibitors nivolumab and dostarlimab. The AMBER Trial that was presented recently, and in full disclosure, both you and I actually are on this abstract. So, what do you think of this abstract? What do you think of the data that is discussed, and how do we contextualize this in relation to what needs to be done in this space?  Dr. Jason Luke: So, I think this is an exciting abstract because it brings forward what may be the next high-priority immune checkpoint to try to target in clinical oncology. To level-set, I think everybody listening will know about PD-1 and CTLA-4 as immune checkpoints. In the last year, we've had LAG-3 come forward as now a standard of care element of armamentarium in melanoma, and we look forward to further studies of LAG-3 and other tumor types as we think it should be a good partner where PD-1 is otherwise approved.  So here now, we hear about TIM-3, which is another negative regulatory checkpoint on a number of different immune subsets. And in this abstract, the antibody targeting TIM-3 was cobolimab. So, TIM-3 is a very interesting molecule. It has, what you might call, pleiotropic effects in the immune system. So, while in the context of this abstract, it was being targeted as another immune checkpoint on T cells, it's important to point out that TIM-3 has other regulatory roles in other immune subsets such as myeloid cells and very particularly dendritic cells, and that's important because it might bring in another element of the innate immune system to try to drive anti-tumor responses. So, it's an exciting target because it might be able to expand the groups of patients who could benefit from immune checkpoint blockade.  So, in this abstract, we see initially the phase 1 data of combining cobolimab, anti-TIM-3 with anti-PD-1 of a couple of different flavors. And what you could take from this abstract is that in the phase 1 setting, the drug was well-tolerated and combined well, and had pharmacokinetic properties that would be consistent with what we'd expect for this kind of a monoclonal antibody. I think we have to marry this abstract, which is really the phase 1 data about safety in pharmacokinetic (PK) to another abstract presented in the melanoma session, which showed an expansion cohort of patients who got cobolimab plus nivolumab or dostarlimab.  And there we did see a 50% response rate, albeit that there was heterogeneity of patients being treatment naïve versus treatment-experienced. So, what I would say to this on a high level is that I think these data are preliminarily exciting, suggesting that further investigation into TIM-3 may be valuable in terms of expanding the population of patients initially in melanoma, but there will data coming soon in lung cancer and in other tumor types with another novel checkpoint. And I think if we think ahead into the future, the question is probably going to end up being, which combinations of checkpoints for which patients. That's pretty exciting to think about. We've seen a lot of data of PD-1 plus other molecules, and I think some future biomarker stratification really will be necessary to know which patient would benefit the most from which of these combos, but for the time being, this is exciting data to see where the field is going to go over the next couple of years.  Dr. Diwakar Davar: Great. And I guess, to your point, one important thing to highlight from the abstract is your point about the role of the different compartments. There was actually a very interesting dose-response relationship with the highest dose of the drug not necessarily being the most effective dose, suggesting that yes, as you escalate, you may have different effects in different compartments, and maybe therefore a broad selection of doses might be required to ensure that you have optimal engagement of the optimal target.  So, the next abstract is Abstract 3007. This is the tumor-agnostic efficacy and safety of erdafitinib. So, we now know that FGFR pathway aberrations are found from 77% of all malignancies, FGFR targets are now U.S. Food and Drug Administration (FDA) approved in cholangiocarcinoma with pemigatinib, infigratinib, and as well with erdafitinib metastatic urothelial cancer. We know that these agents are not necessarily effective tests in 1 tumor type because these alterations have risen in multiple tumor types. So, the RAGNAR trial, looking at this across multiple tumor types, what do you make of the interim analysis result presented by Dr. Loriot?  Dr. Jason Luke: So, I'd say that this is probably the future of targeted therapy. And so, I think that where we have activity in 1 disease, it's very likely we would have activity in others. So, the author has described this as the largest basket trial of a molecularly defined subset that's been pursued to date. There are upwards of more than 200 patients in the study. I think it's really important, as we think about the data, to realize, though, that all FGFR alterations are not exactly the same thing. And so, in this study, they gave erdafitinib to patients with solid tumors of any FGFR altered status. And so that's FGFR1, 2, 3, 4 mutations or gene fusions. And that's a lot of heterogeneity in there actually.  And in this study, there were two-thirds fusions and one-third mutations, mostly in FGFR2 and 3. That will become relevant as we start to think about the results. On a high level, I have to say that it is impressive in pan-cancer fashion, just selecting by FGFR alteration, there's about a 30% response rate observed. I think that no matter what, that's going to be valuable considering these were patients with refractory tumors with 3 lines of prior therapy on median. I think what we need to know more is the breakdown of which specific molecular alteration and FGFR in which tumor types drove most of the benefit.  So, for example, in bladder cancer where erdafitinib is already approved, that's almost entirely an FGFR3 fusion setting. So we know the drug is effective there. And so I think there will be a further breakdown of the data. As it matures more, you really start to tease out, is it really the case that any FGFR alteration can be treated or there are some that really ought to be the high priorities that we really ought to be going after. I think it would be remiss not to also note, however, that while there's excitement about this sort of pan-cancer approach, the current generation of FGFR inhibitors are not exactly the easiest drugs to take.  And so, the in-class, hypophosphatemia and stomatitis really does lead to dose reductions in a lot of the patients. And I think that that's probably really important to emphasize is that despite the pan-tumor activity, there's still a lot of potential in this field to refine further because it's almost certainly the case that if we had less off-target toxicity, so to say, we could improve the efficacy beyond that 30% that we saw here.  All the same, I think this is exciting for the concept of a pan-cancer tumor agnostic sort of approach, and we'll really look forward to more data to come from this study over the next, hopefully, few months.  Dr. Diwakar Davar: And I guess 1 corollary to that is that we now need to start looking for FGFR alterations in multiple tumor types. So, tests, tests, tests. All right, Abstract 3004, phase 1a/1b dose escalation and expansion study of the MDM2-p53 antagonist BI 907828 in patients with multiple solid tumors including advanced, metastatic, liposarcoma. So, we've recently had data of the previously undruggable KRAS, and now we've got previously undruggable p53, for which we now have targets. So, Jason, what do you make of the p53 targeting approach, in this case, using MDM2 and this particular drug from Boehringer Ingelheim?  Dr. Jason Luke: So, I think that this is an exciting abstract exactly for the reason that you mentioned, which is that p53 has been, and unfortunately, to some degree, still remains, one of those holy grails but undruggable targets in oncology. So MDM2, for those who are listening but might not be aware, is a negative regulator of p53. So, the concept here then is if you drug it, you might release p53 to reactivate activity in that pathway, and then p53 being the guardian of the genome, so to say, potentially leading to apoptosis of cancer cells.  And so, this drug binds MDM2 and MDM2 can be amplified as a resistance mechanism in p53 and several tumor types. And so here, they showed data for the early part of a clinical trial investigating the small molecule, BI 907828, but then they focus specifically in liposarcoma, which is a disease known to be an MDM2 amplified. And so, the results were pretty interesting. The toxicity of this kind of an approach, just to note, is really in class. It leads to some gastrointestinal (GI) toxicities as well as hematologic problems, and this goes again for most regulators of the cell cycle will have these effects, whether they're CDK inhibitors or MDM2 or p53 modulators.  But I think what was very interesting, this is a disease liposarcoma where chemotherapy, functionally speaking, has no role. We, unfortunately, give it to some patients sometimes, but it has almost no activity, and they observe that in poorly differentiated liposarcomas, the response rate was about 12%, but the stable disease was quite durable. And so, I think that really is potentially a big deal because this is an orphan disease. It really lacks any other treatment. But as you zoom out from that, if you start to think about targeting amplified MDM2 in other settings, I think the activity that we see here is intriguing, and potentially suggests that we may be coming to a future where we'll have multiple, sort of, orthogonal approaches after reactivating p53. There were actually other abstracts at ASCO Annual Meeting of other molecules that were less mature also along this line.  So, I think, very exciting to take away from this, one, a potential treatment for liposarcoma for all of those patients that anybody listening actually sees, but secondarily this concept of targeting p53, which I think we'll see a lot more of over the next couple of years.  Dr. Diwakar Davar: Excellent. Moving on to the Abstract 3002, this is a phase 1, two-part multicenter, first-in-human study of DS-6000a of an antibody-drug conjugate comprising the anti-CDH6 IgG1 monoclonal antibody that is attached to a topoisomerase I inhibitor payload via a cleavable linker. And so basically, a way in which you can give topoisomerase: (1) TOP1 inhibitor, (2) CDH6-expressing cells. This was studied in advanced renal cell carcinoma (RCC) and advanced ovarian cancer in this abstract presented by Dr. Hamilton. Jason, what do you think of the results and what do you think of this approach in general, this antibody-drug conjugate (ADC) approach using novel targets as well as novel payloads?  Dr. Jason Luke: I think this is one of those that you can't help but be pretty excited about, and I think in the context of the data shown at the plenary session in breast cancer for antibody-drug conjugates (LBA3), I think this is really where the field is going to start to go. So, you mentioned that this is an antibody-drug conjugate that targets cadherin 6 or CDH6, which people will remember from biochemistry class and medical school, or something is a cell-cell adhesion molecule, really a basement membrane protein. So, the concept of targeting it really is just to go after a latch mechanism to get the molecule into the tumor where you want. And CDH expression is very high in renal cell carcinoma, upwards of 80% of samples, also high in ovarian cancer, which is why they chose those 2 tumors to go after.  So, the ADCC, and you described its structure just a little bit, but it's essentially the same backbone as trastuzumab deruxtecan, which we saw this outstanding activity for HER2 and breast cancer on the plenary, with these 8 chemotherapies moieties attached to it, but here now, targeting it instead to HER2, with this molecule now to CDH6. And I think, again, you can't help but be impressed. There were treatment responses on almost every dose level of the dose escalation in this study. There's in fact only 1 patient whose tumor was not, at least, stable disease or a PR, and I think that that just goes to show the power of truly bringing the chemotherapy in a targeted manner into the tumor microenvironment. Responses were heterogeneous. They were not super deep responses per se, but the stable disease was quite durable in the study, and the patients were going out more than 7 months. And again, realizing this is at the lower dose levels as we're increasing the dose and move this in their earlier lives of therapy is likely to be even more effective.  They did show a waterfall plot of the reduction in CA 125 for the patients with ovarian cancer that really looked quite impressive. And given that that's our clinical biomarker that we commonly follow, it may actually even more indicative of the benefit we would see as opposed to resist.  Now, again, there is some toxicity. It is a chemotherapy moiety that's conjugated to the ADCs. So, the most common toxicities were nausea, vomiting, and low platelet counts, but these are kind of toxicities that we're quite accustomed to with chemotherapy. Just to summarize, I think there's a lot of promise for this kind of antibody-drug conjugate targeting, and I think it can only be impressive that they had this amount of activity in the dose escalation of the study. [I] very much look forward to the expansion cohorts in renal and ovarian, which we'll presumably expect to see later this year, early in the next year.  Dr. Diwakar Davar: And as you alluded to, this really was parallel that ASCO, by the standing ovation given to Dr. Modi when she presented the DESTINY04 data of trastuzumab deruxtecan in HER2-low breast cancer, basically now redefining breast cancer from 4 camps, now we have to think of not just HER2 amplified or HER2-high, but also HER2-low. So yes, really have to now rethink how we classify these diseases (LBA3).  So Abstract 2509, the efficacy of anti-PD-1/PD-L1 immunotherapy in non–small cell lung cancer dependent based on CD8 and PD-L1 status. So really Dr. Galon taking us into what he has now described as the immunoscore—really a way of characterizing tumors. A way of thinking about tumors that you've also championed, Jason, in terms of this T cell-inflamed and uninflamed hypothesis. So, tell us a little bit about how these jives with your work and how you would think about lung cancer patients responding and not responding to immune checkpoint inhibitors (ICI) therapy in this context?  Dr. Jason Luke: Yeah. I think the focus quickly here on the immunoscore, so the people are aware of that, I think is really important for diving into these specific results. You have to realize our fundamental underlying predicate for immune checkpoint blockade inhibitor response is that patients have mounted an adaptive immune response. So, CD8 T-cells have gone into the tumor where they elaborate chemokines and cytokines like interferon gamma, which upregulates the expression of PD-L1 in the tumor but also in the surrounding immune cells.  So, you realize that even though antibodies are targeting PD-1, it's really that we're targeting that tumor microenvironment. So, the more robustly we can measure that, and we understand it, the more likely we are to know whether or not the patient is going to benefit. So, this is where the immunoscore comes in. The immunoscore is actually a fairly simple test. It's one slide, immunohistochemistry slide where they can stain jointly for CD8 and PD-L1 on the same slide. And that allows them to do a number of different things beyond just testing the total level of PD-L1. They can test the CD8 density, the PD-L1 expression, but then also the interaction between CD8 T-cells, their distance from each other, from PD-L1 expressing cells, and so on and so forth.  And so really [this] can give us a much more robust analysis of what all is going on in the tumor microenvironment again, off of a single slide. So here then, in this abstract, for patients with non–small cell lung cancer receiving anti-PD-1, they then compared the utility of only PD-L1 testing versus doing the immunoscore. And so, it was actually quite a large set. They had about 250 patients in their analytical set and then split about 150 or 180 or something into the training and validation sets, and they compared the immunoscore against 2 different standard PD-L1 antibodies, the 22C3 as well as the SP263. And what they saw was a high concordance for expression between PD-L1 and the immunoscore.  That's good, because, again, they're measuring PD-L1 in both of those. And so that was a good, sort of, level set. The immunoscore, however, allows them to look to 7 different parameters, again, beyond just PD-L1, as I mentioned. So, CD8 density, interaction, distance, and this kind of thing. Then in these test and training cohorts, they were able to actually split out patients who are PD-L1 positive into further groups, those that were immunoscore low and that were high. And in so doing, they were actually able to sort of dramatically predict the likely progression-free survival on PD-1 checkpoint blockade in those different non–small cell lung cancer groups.  So why is this important? Selection of patients by PD-1 has been very useful in the field of non–small cell lung cancer, but it's hardly a panacea. You're not at all assured your patient is going to do well just because they're PD-L1. And here comes a second assay that can be done in a standard of care setting. So, the immunoscore is a test. You could just order it, and that really does give you much more predictive power about who's likely to do well and who isn't. And I think this test and more broadly multi-spectral imaging is really going to become a core component to how we risk stratify and predict outcomes to checkpoint blockade and lung cancer, but broadly in other tumor types over the next couple of years.  Dr. Diwakar Davar: Okay. Now, moving on from a biomarker for PD-L1 and PD-1 to a setting in which PD-1 was just recently U.S. Food and Drug Administration (FDA)-approved, so I'll give a brief background to the trial that you've actually developed and led. And so, this is KEYNOTE-716, the abstract in question is LBA9500 (late-breaking abstract) 9500, but this is the distant metastasis-free survival (DMFS) data readout. The DMFS, distant metastasis-free survival with pembrolizumab versus placebo in the adjuvant setting for patients with stage IIB or IIC, that is high-risk node-negative melanoma and the data from the phase 3 KEYNOTE-716 study.  So, this data, at least the recurrence-free survival (RFS) data was actually earlier published, you had presented it earlier last year and also more recently this year, but it was published recently in Lancet. And we know that 716 is a study in which, for the first time ever, we have an immune checkpoint inhibitor PD-1 that was studied against placebo with the high-risk node-negative setting in stage IIB and C melanoma, demonstrated a significant RFS benefit in the setting against placebo. And now we have the DMFS readout.  Maybe you could tell us a little bit about both the RFS and the DMFS data, and why this is such an important advance for these patients.  Dr. Jason Luke: Thanks. And I agree this really is a sea change in how we thought about stratification of patients with melanoma, but I think this broadly has implications for other tumor types as well. So, in melanoma, we've historically thought of its involvement of the lymph nodes—stage III as being the high-risk disease, but we also, if you look at the outcomes from the AJCC, we see the patients with stage IIB and IIC, so deep primary lesions, actually have similar bad outcomes as those patients with stage IIIA and IIIB. And so anti-PD1 and adjuvant therapy and melanoma were originally proved for stage III, but having understood that about 5 years ago actually, started to think, well, why not also treat the patients with stage II if they're at similar risk.  And we pursued KEYNOTE-716 as you mentioned, and it read out last year as a positive trial for recurrence-free survival. And the abstract here then was to look at the impact on distant metastasis-free survival. So, while the regulatory consideration for approval, and it is approved and it's available for patients now, was based on relapse, what we really want to be preventing is the development of metastatic disease because presumably that would correlate with the eventual death of the patient from cancer.  So, in the abstract here, we see the first update for DMFS, which also was positive on its first analysis, the hazard ratio at 0.64. And so, again, very similar to the RFS benefit, showing about a 35-36% reduction in distant metastasis-free survival. And this is a theme that we've seen across adjuvant studies in melanoma, all the adjuvant studies in fact, is that the RFS improvement, the relapse-free survival hazard ratio mirrors very closely the distant metastasis-free survival ratio. We saw that again here. I think it just emphasizes that anti-PD-1 immunotherapy is highly effective in melanoma no matter what stage it's in, but rather related to the risk of death for melanoma.  And so this really has a practice changing in the field of melanoma oncology. Patients need to be referred to medical oncology early for discussion around risk stratification and consideration of adjuvant therapy—I think even at the same time that they're having resection of their primary lesion, and it even calls into  question of whether or not we should even fully be doing procedures like sentinel lymph node biopsies any longer, considering we can make the decision to give adjuvant therapy now based on the primary—albeit that's a controversial area of discussion.  And I would just love for this to start to penetrate into other disease settings. We've seen more recently, approval for neoadjuvant therapy in lung cancer and we see in kidney cancer, bladder cancer. We see adjuvant therapy in—I think we're going to see immunotherapy starting to become an important part of the armamentarium in these hard-to-treat cancers, even at the time that perioperatively before or after surgery.  So definitely a major change in the way we're thinking about stratifying patients and emphasizes that you need to get those patients with melanoma in to have that discussion around adjuvant therapy probably at the time of the primary lesion resection.  Dr. Diwakar Davar: And finally, Abstract 2507, single-cell profiling of human heart and blood in patients with checkpoint inhibitor-associated myocarditis. So, this is data from the NGH Group, Dr. Villani and colleagues are presented by Dr. Blum. We know that myocarditis is an uncommon but very serious immune related adverse event (irAE), and here in this particular dataset, this group which has done a lot of underlying work to really uncover the role of certain key phenotypes, cellular phenotypes, in the development of myocarditis it's presenting the data in the context of ICI-related myocarditis. So, what do you think of this data, what do you think of the use of checkpoint inhibitors are now, as you've said, migrated linear in the lifecycle of the patient, what do we need to be thinking about and how does this improve our understanding of both the use of the drug and what we need to be worried about?  Dr. Jason Luke: I think the toxicities of immunotherapy, while, less frequent than, say, chemotherapy, can actually be more disastrous. In the rare patients, we have extreme immune-related adverse events, there is an incidence of actually life-threatening and fatal events. And so, myocarditis, associated with checkpoint blockade, is one of those things that could be seen, and here at ASCO Annual Meeting, we saw a couple of abstracts summarizing the experience from the National Cancer Institute following myocarditis events, and then this abstract in a translational level trying to better understand what is actually going on in terms of the immune response in those myocarditis cases.  And so, I thought this was actually a very interesting abstract. There was only a small number of patients. They had 13 samples from patients who had had endomyocardial biopsies in the context of immune-related myocarditis, and you might say, well, only 13 samples, but fortunately, this is quite a rare event, less than 1% of patients who get immune checkpoint inhibitors. And what they saw was relatively unsurprising, which is that in patients who were having myocarditis, they saw an increase in T cells and in K-cells, as well as activated CD8 and CD4 T-cells.  I think what was very interesting was when they started to dig into what were the phenotypes of the cells and what were the pathways that were turned on. Again, it was not especially surprising to see that they saw increased levels of interferon signaling and immune-receptor signaling as well as motility and adhesion, but this really, I think emphasizes that there are potentially interventions beyond just the general immune-suppression approaches that we give. They could be more nuanced but perhaps more efficacious because sadly, patients do pass away when they develop this. And in their cohort of 13 patients, 3 of those patients died. And specifically, in looking in those 3 patients, they actually saw that all 3 patients had a shared T cell cluster. And they can't exactly say what it is exactly yet, but I think it's very interesting to see that because it suggests that there's probably something about the T cell response in those patients that disproportionately triggered a fatal event.  And if we can understand that better, we then may be able to really tailor our interventions in a way that is more useful. Because, frankly, the way these patients usually present is they show up in the emergency room (ER), and they're seen by an ER doctor who thinks they're having acute coronary. They ship them off to the catheterization (cath) lab. They open him up, and then they get in there, and there's nothing going on. There's no plaque. And so now, all of a sudden, everyone is quite confused. And so, if we had better ways to search for that ahead of time to be aware of it, we might have better interventions because usually what happens right at that moment is everybody gets very confused and starts calling the oncologist, and we start slapping on steroids and other immunomodulatory agents, but sometimes it's late.  So, I think this is a great abstract. It's really starting to preliminary give us an idea of what is the actual biology that underpins these terrible events, and we can hope that we can build off that over time hopefully to eventually come up with better predictors and then obviously better interventions to try to avoid these outcomes in a small but real number of patients.  Dr. Diwakar Davar: Excellent. One other point is you and I are both involved in drug development, and as we start thinking of side effects. Side effects are really on the flip side of responses in drug development. So really 1 point to make of this is that when people start developing side effects rather than, as you say, putting your hands up in the air and waving them around, 1 of the things that we should be doing in drug development is possibly biopsying these patients because we could get new PD insights into how these drugs work, why they work, and particularly which sub-populations themselves they work on, particularly in the early-drug development setting when you oftentimes don't have that many responses.  With that, thank you, Jason, for sharing your insights with us today.  Dr. Jason Luke: Thank you.  Dr. Diwakar Davar: And thank you to our listeners for your time today. If you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. So, thank you for your attention, and we will sign out.      Disclosures:  Dr. Diwakar Davar:   Honoraria: Merck, Tesaro, Array BioPharma, Immunocore, Instil Bio, Vedanta Biosciences  Consulting or Advisory Role: Instil Bio, Vedanta Biosciences  Consulting or Advisory Role (Immediate family member): Shionogi  Research Funding: Merck, Checkmate Pharmaceuticals, CellSight Technologies, GSK, Merck, Arvus Biosciences, Arcus Biosciences  Research Funding (Inst.): Zucero Therapeutics  Patents, Royalties, Other Intellectual Property: Application No.: 63/124,231 Title: COMPOSITIONS AND METHODS FOR TREATING CANCER Applicant: University of Pittsburgh–Of the Commonwealth System of Higher Education Inventors: Diwakar Davar Filing Date: December 11, 2020 Country: United States MCC Reference: 10504-059PV1 Your Reference: 05545; and Application No.: 63/208,719 Enteric Microbiotype Signatures of Immune-related Adverse Events and Response in Relation to Anti-PD-1 Immunotherapy  Dr. Jason Luke:   Stock and Other Ownership Interests: Actym Therapeutics, Mavu Pharmaceutical , Pyxis, Alphamab Oncology, Tempest Therapeutics, Kanaph Therapeutics, Onc.AI, Arch Oncology, Stipe, NeoTX  Consulting or Advisory Role: Bristol-Myers Squibb, Merck, EMD Serono, Novartis, 7 Hills Pharma, Janssen, Reflexion Medical, Tempest Therapeutics, Alphamab Oncology, Spring Bank, Abbvie, Astellas Pharma, Bayer, Incyte, Mersana, Partner Therapeutics, Synlogic, Eisai, Werewolf, Ribon Therapeutics, Checkmate Pharmaceuticals, CStone Pharmaceuticals, Nektar, Regeneron, Rubius, Tesaro, Xilio, Xencor, Alnylam, Crown Bioscience, Flame Biosciences, Genentech, Kadmon, KSQ Therapeutics, Immunocore, Inzen, Pfizer, Silicon Therapeutics, TRex Bio, Bright Peak, Onc.AI, STipe, Codiak Biosciences, Day One Therapeutics, Endeavor, Gilead Sciences, Hotspot Therapeutics, SERVIER, STINGthera, Synthekine  Research Funding (Inst.): Merck , Bristol-Myers Squibb, Incyte, Corvus Pharmaceuticals, Abbvie, Macrogenics, Xencor, Array BioPharma, Agios, Astellas Pharma , EMD Serono, Immatics, Kadmon, Moderna Therapeutics, Nektar, Spring bank, Trishula, KAHR Medical, Fstar, Genmab, Ikena Oncology, Numab, Replimmune, Rubius Therapeutics, Synlogic, Takeda, Tizona Therapeutics, Inc., BioNTech AG, Scholar Rock, Next Cure  Patents, Royalties, Other Intellectual Property: Serial #15/612,657 (Cancer Immunotherapy), and Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)  Travel, Accommodations, Expenses: Bristol-Myers Squibb, Array BioPharma, EMD Serono, Janssen, Merck, Novartis, Reflexion Medical, Mersana, Pyxis, Xilio  Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.     

  I have been in full blown summer mode since school let out…sleeping in, reading for pleasure and days by the pool. It has been incredible, but I am just about ready to spend some time learning. You see, there comes a point every summer where I am ready to get better at being a special educator and spend some time in professional development. Sometimes as a special educator I struggle to find appropriate PD, which can be so frustrating. Where are all the good options?   In this week's episode I am sharing some great ideas for PD that are intended just for you, my special educator friends.    In this episode you will learn: The benefits of completing some PD over the summer. How to balance learning and rest during your break. Where to find PD ideas for special educators. Different types of PD so that you can learn in your way on your time. Links and Resources Amazon Favorites Special Ed Socials Special Ed Professional Development Ideas   Connect with Dawn Find me on IG Etsy Shop TpT Store Subscribe Are you subscribed to my podcast? Trust me, you definitely want to do that so you don't miss a thing! Click here to subscribe in iTunes! Leave a Review If you are loving the podcast, I would be really grateful if you left me a review over on iTunes, too. Those reviews help other teachers find my podcast and I love hearing what you think about the podcast as well. Just click here to review, select “Ratings and Reviews” and “Write a Review” and let me know what part of the podcast you found to be the most helpful!

Welcome to week two of our Short And Sweet Summer episodes! Each week I'll share one quick-win engagement strategy for your third through sixth grade classroom, along with a brain dump of ways YOU can use it!  These SASS-y episodes are great for a quick listen while running errands, or to save up for a big binge on your upcoming flight or road trip! 

프로축구 수원FC 이승우가 우리가 알던 '리틀 메시'의 모습을 되찾고 있습니다. 이승우는 21일 포항전에서 올해의 골로 뽑힐 만한 '180도 터닝슛'으로 골망을 흔들어 수원FC의 2대 1승리를 이끌었습니다. 2004년 독일과 평가전에서 '라이온 킹' 이동국이 터뜨린 발리슛을 떠올리게 하는 환상골이었습니다. 리그 3경기 연속골이자, 7호골로 득점 순위 6위로 올라선 이승우는 득점 뿐 아니라 저돌적인 돌파로 수비를 흔들고 3명의 압박을 화려한 드리블로 뚫어내며 탄성을 자아냈습니다. 리그에서 눈부신 활약을 이어가며 K리그 주축이 된 이승우가 오는 7월 동아시아컵 대표팀 명단에 발탁될지 관심이 커지고 있습니다. 이밖에 지난 주말 K리그를 뜨겁게 달궜던 '현대가 더비'와 '슈퍼매치', 그리고 주중 17라운드 경기 리뷰까지... K리그 소식을 축덕쑥덕에서 함께하세요. 주영민 기자, 주시은 아나운서, 하성룡 기자, 박진형 PD가 참여했습니다. * fb@sbs.co.kr : 여러분의 메일을 기다리고 있습니다. 질문과 사연 많이 보내주세요. 00:07:31 청취자 질문: 영구결번 & 김판곤 감독 관련 00:25:16 이슈 포커스: "의도 없었다" 논란 키운 사과문...폭행으로 얼룩진 슈퍼매치

Featuring articles on PD-1 blockade in locally advanced rectal cancer, a vaccine against respiratory syncytial virus, a vitamin C infusion in adults with sepsis, and reducing administrative harm in medicine; a review article on Philadelphia chromosome–positive acute lymphoblastic leukemia; a case report of a woman with jaundice and chronic diarrhea; and Perspective articles on racial disparity in breast-cancer mortality, on enrollee premiums in Medicaid, on a data infrastructure for clinical trial diversity, on medicalizing the Constitution, and on unexpected closure.

In this bite sized PD, we'll talk about finding fulfillment including: how to find fulfillment as a music teacher resources to help you move forward action steps to take Resources mentioned include: 1. https://www.edutopia.org/blog/rediscovering-your-fulfillment-as-teacher-allen-mendler 2. https://www.thedomesticmusician.com/how-your-background-makes-you-a-better-music-teacher/ 3. https://anchor.fm/thedomesticmusician/episodes/75--How-your-background-makes-you-the-teacher-you-are-today-e92e9s Sign up for the "Teach Elementary Music with Confidence Coaching Week" happening June 26-July 3 right here: https://subscribepage.com/elementarymusiccoachingweek2022

Sho-mama, PD Herman, and Chase Burnin-Too-Many-Bridges are still studio-less but recording! This week they're joined by Ethan Perkins (Church Elder, Father of 4, and Former Youth Pastor.) The 4 discuss a frenzy of topics including Jordans, church growth, Universal Theme Park, PD's shoes, Don Rickles, kings & Queen Latifa, miners & minors, witches, and Harold Potter. Ethan on IG https://www.instagram.com/ethantp/ Mail us something! Church Stories Podcast P.O. Box 14061 Greenville, SC 29610 Join our Patreon for more content! https://www.patreon.com/churchstories e-mail us your written or recorded church stories, and they might make the show for real! churchstoriespod@gmail.com Instagram: https://www.instagram.com/churchstories Twitter: http://bit.ly/churchstoriestwitter Shama: https://linktr.ee/shama4realz PD: http://bit.ly/pdbach Chase: https://linktr.ee/chasebridges --- Send in a voice message: https://anchor.fm/churchstories/message Support this podcast: https://anchor.fm/churchstories/support

I know many of you might be expecting a normal Geektown Radio episode this week, but unfortunately, we had to skip it due to timing issues. We usually record on Mondays, and I was in London interviewing the cast of Halo (watch out for that interview coming soon!)However, to tide you over until next week, we have an interview with Stunt Coordinator Matt LeFevour, who has worked on a huge array of tv shows and movies, both performing and coordinating stunt work. He was stunt coordinator on the Apple TV+ series 'Shining Girls', Showtime series 'The Chi', along with working on Chicago Fire, Med and PD. On the film side, Matt stunt coordinated Aaron Sorkin's six-time Oscar-nominated feature 'The Trial of the Chicago 7' which earned him a SAG Award nomination for Outstanding Action Performance by a Stunt Ensemble. He has also worked on various comic book projects including almost all of the Batman films from 'Batman Begins' through to 'The Batman', where he served as assistant stunt coordinator. In addition to all that, he is Chris Hemsworth's stunt double for many of his movies, including the 'Thor' films and other appearances in the MCU. He is currently working on 'Power Book IV: Force', and was stunt coordinator on 'Mike', the upcoming Hulu drama based on the life of heavyweight champion Mike Tyson.Support this show http://supporter.acast.com/geektown. See acast.com/privacy for privacy and opt-out information.

PD and Dale discuss the latest Columbus signings, including: What happened to Liam Foudy? Can Daniil Tarasov challenge Elvis in a few years? Colorado's dominance (recorded prior to Game 3, naturally) Who will win the final NHL awards on Tuesday night? Check out more from The Cannon on our site and on Twitter. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Topics: Three out of four Americans behind bars are forced to work for free or little to no money; The history of Juneteenth; The 13th Amendment's loophole; The Police Myth; Cops solve only one percent of all crimes; What is the real role of police in America?; Solitary confinement Guests With Time Stamps (02:04) David Does the News (56:30) "USA of Distraction" written and performed by Professor Mike Steinel (1:02:47) Jason Myles and Pascal Robert (co-hosts of "This is Revolution" podcast) (1:56:53) Howie Klein (founder and treasurer of The Blue America PAC and author of Down With Tyranny) (2:29:02) "Travelin' Light" written and performed by Professor Mike Steinel (2:32:48) David Cobb (environmental activist and Green Party Presidential candidate) Is there a voting block of Fox News right wingers who would come out from the shadows to support Bernie and single payer healthcare? (2:58:13) Dr. Harriet Fraad (host of "Capitalism Hits Home") How the fall of the American empire effects our mental health. (3:33:18) Peter B. Collins (Bay Area Radio Hall of Fame) Dems facing the loss of the House, and probably Senate in November, and Biden's latest moves are making things worse. While he called out price gouging by US oil companies last week, he won't do anything about it. And he's going to kiss MBS, trading humiliation for oil, which the oil companies will price gouge anyway. (4:03:46) Professor Adnan Husain ("Guerrilla History" and "The Majlis" podcasts) Yesterday's French parliamentary election results. Sweden wants to join NATO, and why Turkey objects. Muslim Indian demonstrations against BJP government officials under Modi and their repression. (4:50:19) Professor Mike Steinel (Jazz historian and Dylanologist) We livestream here on YouTube every Monday and Thursday starting at 5:00 PM Eastern and go until 11:00 PM. Please join us! Take us wherever you go by subscribing to this show as a podcast! Here's how: https://davidfeldmanshow.com/how-to-l... And Subscribe to this channel. SUPPORT INDEPENDENT MEDIA: https://www.paypal.com/biz/fund?id=PD... More David @ http://www.DavidFeldmanShow.com Get Social With David: Facebook: http://www.facebook.com/davidfeldmanc... Twitter: https://twitter.com/David_Feldman_ iTunes: https://itunes.apple.com/us/podcast/d...

As coaches, we work tirelessly to support our teachers and students in the classroom. There are coaches all across the world that provide this support everyday! Today, we take a look at one coach's journey through multiple countries on multiple continents and learn how coaching is both the same and different throughout the world.Forward Edge Coaches Camp Registration - RRPODCAST for $50 off.Follow  Amy on TwitterPodcast TeamHosts- Katie  Ritter & Justin ThomasEditing Team- Michael Roush Social Media/ Promo Team- Annamarie Rinehart, Lisa Kuhn, Maggie HarrisCreative/Content Team- Brooke Conklin, Emily Cowan, Tracee KeoughProducers- Justin ThomasEdge•U Badges Edge•U is an anytime, anywhere professional learning platform made for teachers by teachers!Coach Mentorship Program Year-long mentorship programs to support the ultimate PD provider: instructional coaches!

This week's EYE ON NPI is very adaptable - it's CUI Inc's 30 W Desktop USB PD Adapters (https://www.digikey.com/en/product-highlight/c/cui/30-w-desktop-usb-pd-adapters) which have up to 30 Watts of output with a variety of voltages, so they can be used in multiple product designs to make your inventory and procurement simpler! These power adapters will help you transition your products from DC jacks to USB C, which has power negotiation all in one consistent, well-recognized connector. We've covered DC plug adapters on EYE ON NPI before. Just about every product in the world uses these ubiquitous 'barrel jack' connectors for power (https://www.digikey.com/en/products/filter/ac-dc-desktop-wall-adapters/130): often 5.5mm outer diameter / 2.1 or 2.5mm inner (https://www.digikey.com/en/products/detail/cui-devices/PJ-003A/96969). These connectors are so popular that they don't really 'mean' anything when you see them other than "power connector". There's no inherent voltage, polarity or current capability that is indicated by a barrel jack. You could have 5VDC center-positive 5A adapter (https://www.digikey.com/en/products/detail/cui-inc/SDM36-5-U-P5/8547877) or you could have a 9VAC 300mA adapter, all with the same connector. Only by careful reading and matching of the labels can you verify which adapter you have matches with which product - and if you lose the adapter it could be a real pain to get a replacement. That's where USB Type C has a lot of potential to improve and simplify this issue: folks end up being scared to toss out their power adapters because you never know when you need it or what the matching devices is, even years later. If, instead, we had one power adapter and cable that would be usable for any product, that would deliver the right voltage, we could mix and match adapters without worrying about under-powering or over-volting. A lot of mobile devices have started to go this way with USB mini or micro B ports, cell phones being the most popular: all USB ports are basically 5V 1A (https://www.digikey.com/en/products/detail/cui-inc/SWI5-5-N-I38/5287192) and if you have something running off of a Lipoly battery, this is plenty to keep you topped up. But for larger devices, ones with displays or motors, or larger battery packs, 5W (or 10W on a fancy high current adapter) is not going to be enough. And you don't necessarily want 5V input! If you have a backlight that requires 12V or a battery pack that is 8.4V it's going to be expensive and wasteful to try and boost 5V USB up to 12V. USB C's Power Delivery spec is a great solution: it can provide anywhere from 5V to 20V DC, at up to 100W if the power adapter is chunky enough. CUI's awesome blog has a great post about the power delivery specifications with clear text and diagrams (https://www.cui.com/blog/usb-type-c-pd-and-pps) for more info - in particular watch out that you have a current limitation or 3A or 5A at each voltage so you'll never be able to get 5V 20A = 100W. Instead you'd get 20V at 5A. However, if your voltage / wattage use case lies within the PD requirements, you're good to go! You can use a standard USB C connector (https://www.cuidevices.com/catalog/interconnect/connectors/usb-connectors), standard USB C power cables (https://www.cuidevices.com/catalog/interconnect/cable-assemblies/usb-cables?[0].sn=Connector%201&[0].sv=Type%20C%20Plug) - all available from CUI and the CUI 30 W Desktop USB PD Adapter (https://www.digikey.com/short/v0f7fqm2) as the power supply. Best of all, Digi-Key has tons of CUI 30 W Desktop USB PD Adapters (https://www.digikey.com/short/v0f7fqm2) in stock, the version we're linking to comes with a USA power cable, but they also sell a version without a cable (https://www.digikey.com/en/products/detail/cui-inc./SDI30C-Q-UTB-CUB/16376426) so you can swap out with a UK, EU or other wall plug. Don't forget to also get a high quality CUI USB Type C connector (https://www.digikey.com/short/w23hh4m4) to go with. Order today for immediate shipment!

What does Parkinson's Disease look like? Or rather who does it look like?In this new series Judy and Travis speak to people with People with Parkinson's disease and help them to share their journey through PD with you.In this episode we talk to Terry Montelibano, a retired teacher who shared with us whaat it was like getting her diagnosis during the COVID-19 pandemic. Enjoy. 

เขียนนิยายวายว่ายากแล้ว แต่การสร้างจักรวาลวายของตัวเองให้เชื่อมโยงกันนี่สิยากกว่า ยิ่งจักรวาลวายในวงการวิชาชีพอย่าง “หมอ” ด้วยแล้ว โอ้โห ดับเบิ้ลความยากเข้าไปหลายตลบ PD พี่ตั้มและ CO-HOST น้องเนยเลยชวนฟัง “พญ.อิสรีย์ ศิริวรรณกุลธร” หรือนักเขียนนามปากกา Sammon ผู้ฝากผลงานจักรวาลวายข้างต้น ทั้งพฤติการณ์ที่ตาย ทริอาช และเรื่องอื่นๆ ที่บอกเลยว่า งานนี้ไม่หมูสำหรับเธอเลย #SalmonPodcast #WorldY #โลกทั้งใบให้วายอย่างเดียว #พี่ตั้มน้องเนย #Sammon #พฤติการณ์ที่ตาย #MannerofDeath #ทริอาช #Triage Learn more about your ad choices. Visit megaphone.fm/adchoices

This week's guest, Noah Daniel, shares how in her leadership journey, she needed mentors to provide guidance, wisdom, and inspiration to build beyond her position and explore new opportunities.  In this episode, we discuss: TEDx Talk about Personal Narrative Music Project Extending Beyond Her Comfort Zone And her book, Strum and the Wild Turkeys About Noa Daniel: Noa Daniel MEd, is a classroom teacher in the York Region District School Board outside Toronto, Canada. Through her consulting work at https://buildingoutsidetheblocks.com/ (Building Outside the Blocks) she creates personalizing projects and initiatives for schools, boards, and communities. Noa is the Co-Founder and Executive Director of http://thementoree.com/ (The Mentoree). She is also a https://buildingoutsidetheblocks.com/boblog (blogger), a children's book author and podcaster. Noa's children's books include Crazy for Canada, Old Timers: The One That Got Away, and her newest, http://strumandthewildturkeys.com/ (Strum and The Wild Turkeys), through EduMatch Publishing. Noa hosts https://voiced.ca/project/onedmentors/ (OnEdMentors) on voicEd Radio and the former show, https://www.spreaker.com/show/the-personal-playlist-podcast (The Personal Playlist Podcast). She is also a https://www.ted.com/talks/noa_daniel_play_it_forward (TEDx )and keynote speaker. As a board member of https://www.learningforwardontario.ca/ (Learning Forward Ontario), Noa strives to contribute to meaningful professional learning opportunities for educators. All of Noa's work amplifies voice and propels engagement for learners of all ages. She is always building outside the blocks. Follow Noa Daniel Website: http://www.buildingoutsidetheblocks.com (www.buildingoutsidetheblocks.com) Twitter: @iamnoadaniel @strumandtwt @thementoree Instagram: @iamnoadaniel @strumandtwt @thementoree Linkedin: Noa Daniel YouTube: The Mentoree, Strum and The Wild Turkeys https://www.amazon.com/Strum-Wild-Turkeys-Noa-Daniel/dp/1953852203?_encoding=UTF8&qid=1655584156&sr=1-1&linkCode=ll1&tag=aspirewebsite-20&linkId=08aac7ba9e4019769f31570e76e3a8a4&language=en_US&ref_=as_li_ss_tl [caption id="attachment_3508" align="alignnone" width="1024"]https://joshstamper.com/wp-content/uploads/2021/06/Aspire-Swag-Website-Image-update-6.18.21.png () Aspire: The Leadership Development Podcast Swag, Joshua Stamper, Teach Better[/caption]   NEW Aspire Swag with Discount Code: ASPIRE  Tee-Shirts and Drinkware: https://teachbetterswag.com/collections/aspire-the-leadership-development-podcast (ASPIRE: The Leadership Development Podcast)   This post contains affiliate links. When you make a purchase through these links, The Aspire Podcast gets a small percentage of the sale at no extra cost to you. Need a Presenter for a conference or school PD? https://joshstamper.com/contact/ (Contact Joshua Stamper ) for presentations on Restorative Practices, Leadership Development, and Innovative campus systems. Watch my session on Trauma Informed, restorative and social emotional practices athttp://www.teachsummit.com/stamper ( www.teachsummit.com/stamper)   Follow the Host, Joshua Stamper: Contact:https://joshstamper.com/contact/ ( https://joshstamper.com/contact/) Twitter:http://www.twitter.com/Joshua__Stamper ( www.twitter.com/Joshua__Stamper) Instagram:http://www.instagram.com/joshua__stamper ( www.instagram.com/joshua__stamper) Linkedin:http://www.linkedin.com/in/joshua-stamper/ ( www.linkedin.com/in/joshua-stamper) Facebook:https://www.facebook.com/AspirePodcast ( https://www.facebook.com/AspirePodcast) Subscribe:https://podcasts.apple.com/us/podcast/aspire-the-leadership-development-podcast/id1384210762?mt=2 ( https://podcasts.apple.com/us/podcast/aspire-the-leadership-development-podcast/id1384210762?mt=2)   Aspire to Lead made it to the Best New Education Books [caption...